These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 17195089

  • 1. Histone deacetylase inhibitors enhance Ad5-TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activity.
    VanOosten RL, Earel JK, Griffith TS.
    Apoptosis; 2007 Mar; 12(3):561-71. PubMed ID: 17195089
    [Abstract] [Full Text] [Related]

  • 2. Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors.
    VanOosten RL, Earel JK, Griffith TS.
    Cancer Gene Ther; 2006 Jun; 13(6):628-32. PubMed ID: 16456549
    [Abstract] [Full Text] [Related]

  • 3. Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts.
    Vanoosten RL, Moore JM, Ludwig AT, Griffith TS.
    Mol Ther; 2005 Apr; 11(4):542-52. PubMed ID: 15771957
    [Abstract] [Full Text] [Related]

  • 4. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
    Wohlfahrt ME, Beard BC, Lieber A, Kiem HP.
    Cancer Res; 2007 Sep 15; 67(18):8783-90. PubMed ID: 17875719
    [Abstract] [Full Text] [Related]

  • 5. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells.
    Earel JK, VanOosten RL, Griffith TS.
    Cancer Res; 2006 Jan 01; 66(1):499-507. PubMed ID: 16397266
    [Abstract] [Full Text] [Related]

  • 6. Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8.
    Häcker S, Dittrich A, Mohr A, Schweitzer T, Rutkowski S, Krauss J, Debatin KM, Fulda S.
    Oncogene; 2009 Sep 03; 28(35):3097-110. PubMed ID: 19597472
    [Abstract] [Full Text] [Related]

  • 7. In vitro efficacy of AdTRAIL gene therapy of bladder cancer is enhanced by trichostatin A-mediated restoration of CAR expression and downregulation of cFLIP and Bcl-XL.
    El-Zawahry A, Lu P, White SJ, Voelkel-Johnson C.
    Cancer Gene Ther; 2006 Mar 03; 13(3):281-9. PubMed ID: 16167063
    [Abstract] [Full Text] [Related]

  • 8. Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways.
    Shankar S, Singh TR, Fandy TE, Luetrakul T, Ross DD, Srivastava RK.
    Int J Mol Med; 2005 Dec 03; 16(6):1125-38. PubMed ID: 16273296
    [Abstract] [Full Text] [Related]

  • 9. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells.
    Nakata S, Yoshida T, Horinaka M, Shiraishi T, Wakada M, Sakai T.
    Oncogene; 2004 Aug 19; 23(37):6261-71. PubMed ID: 15208660
    [Abstract] [Full Text] [Related]

  • 10. E1A sensitizes cancer cells to TRAIL-induced apoptosis through enhancement of caspase activation.
    Shao R, Lee DF, Wen Y, Ding Y, Xia W, Ping B, Yagita H, Spohn B, Hung MC.
    Mol Cancer Res; 2005 Apr 19; 3(4):219-26. PubMed ID: 15831675
    [Abstract] [Full Text] [Related]

  • 11. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
    Ravi R, Bedi A.
    Cancer Res; 2002 Aug 01; 62(15):4180-5. PubMed ID: 12154014
    [Abstract] [Full Text] [Related]

  • 12. Combination of vorinostat and adenovirus-TRAIL exhibits a synergistic antitumor effect by increasing transduction and transcription of TRAIL in lung cancer cells.
    Kim DR, Park MY, Lee CS, Shim SH, Yoon HI, Lee JH, Sung MW, Kim YS, Lee CT.
    Cancer Gene Ther; 2011 Jul 01; 18(7):467-77. PubMed ID: 21455254
    [Abstract] [Full Text] [Related]

  • 13. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
    Zhang XD, Wu JJ, Gillespie S, Borrow J, Hersey P.
    Clin Cancer Res; 2006 Feb 15; 12(4):1355-64. PubMed ID: 16489094
    [Abstract] [Full Text] [Related]

  • 14. The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis.
    Griffith TS, Kemp TJ.
    Cancer Chemother Pharmacol; 2003 Sep 15; 52(3):175-84. PubMed ID: 12811515
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells.
    Sonnemann J, Kumar KS, Heesch S, Müller C, Hartwig C, Maass M, Bader P, Beck JF.
    Int J Oncol; 2006 Mar 15; 28(3):755-66. PubMed ID: 16465382
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
    Ng CP, Zisman A, Bonavida B.
    Prostate; 2002 Dec 01; 53(4):286-99. PubMed ID: 12430140
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.